RxDoctor Payments Data

Weiyi Gao, MD

Neurology · Flushing, NYNPI 1760642961

Payments from drug & device makers

$5,486in general payments, 2019–2025

Across 260 payments — averaging $21.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • UCB, Inc.$901
  • Eisai Inc.$510
  • Amneal Pharmaceuticals LLC$272
  • Johnson & Johnson$202
  • Lilly USA, LLC$163
  • plus $894 from 13 others

What the payments were for

  • Food & beverage$5,486100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,486 in reported general payments places this provider in the 65th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$34,294
Medicare patients
165
Services billed
491

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Diclofenac Epolamine105$51,407
RytaryCarbidopa/Levodopa59$43,119
NeuproRotigotine23$18,717
Mirtazapine618$17,987
Gabapentin1,654$13,242
BotoxOnabotulinumtoxina14$11,212
BelsomraSuvorexant18$7,477
Carbidopa-LevodopaCarbidopa/Levodopa424$7,068
Diclofenac Sodium123$6,564
Rasagiline Mesylate31$5,417
VascepaIcosapent Ethyl18$5,038
Donepezil Hcl897$4,947
Entacapone58$4,177
Memantine Hcl410$3,742
RivastigmineRivastigmine Tartrate129$3,621

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$272$44,18675 claims
UCB, Inc.Neupro$901$18,71723 claims
AbbVieBotox$2,544$11,21214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,623 neurology providers in New York.

Other neurology in Flushing

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →